Exenatide vs Matrixyl
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Matrixyl is the most widely used collagen-stimulating cosmetic peptide. As a matrikine — a fragment of type I procollagen — it signals skin cells to synthesize new collagen, elastin, and fibronectin, reducing wrinkle depth and improving skin firmness and elasticity.
- Half-Life
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- N/A — topical; sustained signaling effects on fibroblasts persist beyond single application
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 5 mcg, titrate to 10 mcg
- 3–8% concentration
- Frequency
- Twice daily
- Once or twice daily
- Key Benefits
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Stimulates collagen I, III, and IV synthesis
- Increases fibronectin and glycosaminoglycan production
- Reduces wrinkle depth and length by 27–68% (studies)
- Improves skin firmness and elasticity
- Reduces dark circles and undereye bags
- Synergistic with retinol, vitamin C, and growth factors
- Suitable for all skin types including sensitive
- Well-studied with published clinical data
- Side Effects
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Exceptional safety profile
- Non-irritating, suitable for sensitive skin
- No known adverse effects at cosmetic concentrations
- Stacks With
- —
- —